HHSN261201400051C;TOPIC 309 DEVELOPMENT OF LOW COST, SMALL SAMPLE MULTI-ANALYTE TECHNOLOGIES FOR CANCER DIAGNOSIS, PROGNOSIS AND EARLY DETECTION;TITLE: FLOWNOSTICS: PORTABLE MULTIPLEX ANALYSIS SYSTEM;

癌症是一种复杂多样的疾病，其治疗可以通过更复杂的早期治疗来改善。 检测和监测。NanoCeliect Biomedical，Inc.建议建立一个芯片实验室微流体装置 该平台可以检测和定量至少32种多重分析物，用于检测和监测 血液或尿液样本的癌症。这种新颖的“FlowNostics”装置将利用32种微观珠， 通过它们的大小和颜色进行编码，将由阻抗和单个光学检测器的组合检测 以检测来自单个405 nm激光激发的发射。NanoCellect的FlowNostics平台将减少 基于流式细胞术的多重测定的费用和复杂性，以增加可及性并实现即时护理 诊断 NanoCellect的FlowNostics技术将改善公众健康，并有助于完成NIH的使命， NCI通过改进对复杂分析的访问，而成本和复杂性仅为当前设备的一小部分。 NanoCellect的目的是能够报告在癌症治疗期间采集的常规血液样本中存在癌症。 检查，这将有助于早期发现癌症，并允许在癌症达到严重程度之前进行治疗。 晚期

Cancer is a complex and diverse disease whose treatment can be improved by more sophisticated early detection and monitoring. NanoCeliect Biomedical, Inc. proposes to build a lab-on-a-chip microfluidic device platform that can detect and quantify at least 32 multiplexed analytes for the detection and monitoring of cancer from blood or urine samples. This novel "FlowNostics" device will utilize 32 kinds of microscopic beads, coded by their size and color, that will be detected by a combination of impedence and a single optical detector to detect emission from single 405 nm laser excitation. NanoCellect's FlowNostics platform will reduce the expense and complexity of flow cytometric-based multiplex assays to increase access and enable point-of-care diagnostics. NanoCellect's FlowNostics technology will improve public health and help to fulfill the mission of the NIH and NCI by improving access to sophisticated analytics at a fraction of the cost and complexity of current devices. NanoCellect's aim is to enable reporting of the presence of cancer from routine blood samples taken during check-ups, which will aid in the early detection of cancer and allow treatments before cancers have reached an advanced stage.